trial · primary record
MCLA-129
Non-Small Cell Lung Cancer Metastatic
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 194 |
| Primary completion | 2026-10-01 |
| Primary endpoint | To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) |
| Registry ID | NCT04868877 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:49.800Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04868877
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.